Everything below concerns HGF mimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
The Rockefeller Foundation continued funding German eugenics research even after it was clear that it was being used to rationalize discrimination against Jewish people and other groups, after the Nuremberg laws in 1935. In 1936, Rockefeller fulfilled pledges of $655,000 to Kaiser Wilhelm Institute, even though several distinguished Jewish scientists had been dropped from the institute at the time. The Rockefeller Foundation did not alert the world about the racist implications of Nazi ideology, but furthered and funded eugenic research through the 1930s. Even into the 1950s, Rockefeller continued to provide some funding for research borne out of German eugenics. The foundation also funded the relocation of scholars threatened by the Nazis to America in the 1930s, known as the Refugee Scholar Program and the Emergency Committee in Aid of Displaced Foreign Scholars. Some of the notable figures relocated or saved, among a total of 303 scholars, were Thomas Mann, Claude Lévi-Strauss and Leó Szilárd. The foundation helped The New School provide a haven for scholars threatened by the Nazis.
=== Prehistory and Imperial China === The earliest known human traces in what is now Hong Kong are dated by some to 35,000-39,000 years ago during the Paleolithic period. The claim is based on an archaeological investigation in Wong Tei Tung in the Sai Kung Peninsula in 2003. The archaeological works revealed knapped stone tools from deposits dated by optical luminescence dating. During the Middle Neolithic period, about 6,000 years ago, the region had been widely occupied by humans. Neolithic to Bronze Age Hong Kong settlers were semi-coastal people. Early inhabitants are believed to have been Austronesians in the Middle Neolithic period, and later the Yue people. As hinted by the archaeological works in Sha Ha, Sai Kung, rice cultivation had been introduced since the Late Neolithic period. Bronze Age Hong Kong featured coarse pottery, hard pottery, quartz and stone jewelry, as well as small bronze implements.
S. affinis is planted as a bulb (vegetative) in spring (March–May). Multiple bulbs are planted 5 to 8 cm (2 to 3+1⁄8 in) deep into a hole of dimensions 30 by 30 cm (12 by 12 in). The plant can achieve a height of 30 cm (12 in). Weeding is necessary but it is important not to damage the root system. A sufficient water supply during summer is important. Harvest is from November to March. It is important that the soil is not frozen when harvesting. The storage of S. affinis tubers is difficult. Because of their thin skin, they can be stored only for a few days, about a week in a fridge. An alternative can be a fresh ongoing harvesting out of humid sand, thereby the tubers stay fresh for several months.
Sources: en.wikipedia.org
== Awards and honours == Uhlmann was elected a Fellow of the Royal Society (FRS) in 2015. His certificate of election reads: Frank Uhlmann's discovery with Nasmyth of 'separase', the protease that cleaves the cohesive links between sister chromatids to trigger anaphase is a key contribution to our understanding of the cell cycle. He has made major contributions to our understanding of the mechanisms of sister chromatid cohesion, and their relationship to cell cycle regulation. He generated the first chromosome-wide high resolution maps of proteins involved in chromosome packaging and segregation. He showed that yeast cohesins accumulate at sites of converging transcription distinct from the sites where their loading factors bind, apparently reflecting interaction with the transcription apparatus; and that cohesin loading factors are recruited to specific chromosomal sites through interaction with the nucleosome remodelling complex Rsc. He has identified genes required for cohesion establishment, and shown that one of these, EcoI, acetylates cohesin during DNA replication, thereby locking it onto DNA and his studies of the link between cohesion regulation and the cell cycle have shown that as well as cleaving cohesin, separase promotes mitotic exit by activating the Cdc14 phosphatase in a protease-independent manner. In 2006, Uhlmann was also elected a member of the European Molecular Biology Organization (EMBO) and awarded the EMBO Gold Medal.
The three hearts are also temperature and oxygen dependent and the beat rhythm of the three hearts are generally in phase with the two branchial hearts beating together followed by the systemic heart. The Frank–Starling law also contributes to overall heart function, through contractility and stroke volume, since the total volume of blood vessels must be maintained, and must be kept relatively constant within the system for the heart to function properly. The blood of the octopus is composed of copper-rich hemocyanin, which is less efficient than the iron-rich hemoglobin of vertebrates, thus does not increase oxygen affinity to the same degree. Oxygenated hemocyanin in the arteries binds to CO2, which is then released when the blood in the veins is deoxygenated. The release of CO2 into the blood causes it to acidify by forming carbonic acid. The Bohr effect explains that carbon dioxide concentrations affect the blood pH and the release or intake of oxygen. The Krebs cycle uses the oxygen from the blood to break down glucose in active tissues or muscles and releases carbon dioxide as a waste product, which leads to more oxygen being released. Oxygen released into the tissues or muscles creates deoxygenated blood, which returns to the gills in veins. The two brachial hearts of the octopus pump blood from the veins through the gill capillaries. The newly oxygenated blood drains from the gill capillaries into the systemic heart, where it is then pumped back throughout the body.
=== Ga–Gl === Johan Gadolin (1760–1852), Finnish chemist who discvered yttrium Joseph Louis Gay-Lussac (1778–1850), French chemist and physicist who discovered the Gay-Lussac law, known for discovering that water is made of two parts hydrogen and one part oxygen by volume Charles Frédéric Gerhardt (1816–1856), French chemist known for reforming the notation for chemical formulas, and for synthesizing acetylsalicylic acid (aspirin) Jnan Chandra Ghosh (1894–1959), Indian chemist known for research on strong electrolytes and the dissociation--ionization theory William Giauque (1895–1982), 1949 Nobel Prize in Chemistry for studies of the properties of matter at temperatures close to absolute zero Josiah Willard Gibbs (1839–1903), American chemist and physicist whose work on thermodynamics helped to transform physical chemistry into a rigorous deductive science Walter Gilbert (born 1932), 1980 Nobel Prize in Chemistry for a method of sequencing nucleic acids Cornelia Gillyard (born 1941), American organic chemist known for work with chemicals in the environment Henry Gilman (1893–1986), American chemist who developed organometallic chemistry, and discovered the Gilman reagent Judith Giordan (Thesis 1980), American chemist who worked on unsaturated hydrocarbons and became President-Elect of the American Chemical Society Johann Rudolf Glauber (1604–1670), Dutch-German alchemist and chemist who discovered sodium sulfate and wrote many books Lawrence E. Glendenin (1918–2008), American chemist, co-discovered the element promethium
Inhalation of environmental and occupational pollutants, such as metals in asbestosis, silicosis, and exposure to certain gases. Coal miners, ship workers and sand blasters, among others, are at higher risk. Hypersensitivity pneumonitis, most often resulting from inhaling dust contaminated with bacterial, fungal, or animal products Cigarette smoking can increase the risk or make the illness worse. Smoking is a known cause of some types of lung fibrosis, such as smoking-related interstitial fibrosis (SRIF). Some typical connective tissue diseases such as rheumatoid arthritis, ankylosing spondylitis, SLE and scleroderma Other diseases that involve connective tissue, such as sarcoidosis and granulomatosis with polyangiitis Infections, including COVID-19 Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, apomorphine, and nitrofurantoin Radiation therapy to the chest
This all-or-nothing property of the action potential sets it apart from graded potentials such as receptor potentials, electrotonic potentials, subthreshold membrane potential oscillations, and synaptic potentials, which scale with the magnitude of the stimulus. A variety of action potential types exist in many cell types and cell compartments as determined by the types of voltage-gated channels, leak channels, channel distributions, ionic concentrations, membrane capacitance, temperature, and other factors. The principal ions involved in an action potential are sodium and potassium cations; sodium ions enter the cell, and potassium ions leave, restoring equilibrium. Relatively few ions need to cross the membrane for the membrane voltage to change drastically. The ions exchanged during an action potential, therefore, make a negligible change in the interior and exterior ionic concentrations. The few ions that do cross are pumped out again by the continuous action of the sodium–potassium pump, which, with other ion transporters, maintains the normal ratio of ion concentrations across the membrane. Calcium cations and chloride anions are involved in a few types of action potentials, such as the cardiac action potential and the action potential in the single-cell alga Acetabularia, respectively. Although action potentials are generated locally on patches of excitable membrane, the resulting currents can trigger action potentials on neighboring stretches of membrane, precipitating a domino-like propagation.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.